Memphasys

Memphasys Asset Growth

The Year-over-Year Total Asset Growth of Memphasys (MEM.AX) as of Oct 18, 2026 is 1.94 %. In the previous year, Year-over-Year Total Asset Growth was -11.33 % — a change of -117.13% (higher).

Asset Growth

1.94 %

YoY

-117.13%

Last updated:

Year-over-Year Total Asset Growth of Memphasys is 2026 1.94 % . Year-over-Year Total Asset Growth of Memphasys was 2025 -11.33 % . It decreases by -117.13% higher compared to the previous year.

The Memphasys Asset Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Asset Growth
Date
Asset Growth
Jan 1, 2019
62.11 AUD
Jan 1, 2020
65.27 AUD
Jan 1, 2021
29.05 AUD
Jan 1, 2022
-3.15 AUD
Jan 1, 2023
3.87 AUD
Jan 1, 2024
-15.26 AUD
Jan 1, 2025
-11.33 AUD
Jan 1, 2026
1.94 AUD
The Memphasys Asset Growth history
YEARAsset GrowthYoY
1.94 %-117.13%
-11.33 %-25.75%
-15.26 %-494.04%
3.87 %-222.80%
-3.15 %-110.85%
29.05 %-55.49%
65.27 %+5.09%
62.11 %-247.03%
-42.24 %-2,934.78%
1.49 %-70.86%
5.11 %-240.82%
-3.63 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Memphasys Stock analysis

What does Memphasys do? Memphasys Ltd, listed on the Australian Securities Exchange under the ticker MEM.AX, is a life sciences company headquartered in Homebush West, New South Wales. The company went public via an IPO on May 14, 2007. Memphasys operates within the Health Care sector, specifically in the Life Sciences Tools & Services industry. The company focuses on developing medical devices, diagnostics, and media for applications in assisted reproduction technology (ART) for both humans and animals. Its product pipeline includes several developments, such as Felix, ROSA, and AI-Port. Felix is a patented, automated device designed to separate high-quality sperm from semen for human in vitro fertilization (IVF) procedures, aiming to avoid DNA damage. ROSA functions as an in vitro diagnostic tool to evaluate semen and blood samples for oxidative stress. AI-Port is a system for storing and transporting animal semen for artificial insemination (AI) in livestock, capable of maintaining semen viability for up to four days without freezing, which is a common practice in standard AI procedures. The company's products target global markets, particularly in the field of reproductive biotechnology, with specific applications in both human and animal reproductive health. Memphasys operates with a focus on innovation in reproductive technology, leveraging proprietary media and diagnostic tools to address challenges in assisted reproduction. Memphasys is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Memphasys stock

Year-over-Year Total Asset Growth of Memphasys is 1.94 % in 2026.

On Eulerpool you can find the complete historical development of Year-over-Year Total Asset Growth Memphasys since 2006 – with annual values, charts, and detailed analysis.

Asset growth measures the percentage change in total assets. Rapid asset growth may indicate expansion but can also correlate with lower future returns.

To evaluate Year-over-Year Total Asset Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Total Asset Growth.

Year-over-Year Total Asset Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Total Asset Growth's Memphasys historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Memphasys

All Key Metrics — Memphasys